Get the Stockscreener App
1,023.22
0.26%
2.66
After Hours:
1024.03
0.81
+0.08%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,023.22, with a volume of 2.14M.
It is up +0.26% in the last 24 hours and down -1.46% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,020.56
Open:
$1010.82
24h Volume:
2.14M
Relative Volume:
0.65
Market Cap:
$965.26B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
45.30
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-1.45%
1M Performance:
-1.46%
6M Performance:
+45.51%
1Y Performance:
+18.01%
1-Day Range:
$1,007.00
$1,025.22
1-Week Range:
$1,007.00
$1,067.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,023.22 | 962.75B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.91 | 590.40B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.35 | 404.24B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
208.62 | 323.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.92 | 315.57B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity - Finviz
Warning: This Skyrocketing Stock Has a Hidden Risk - AOL.com
Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients - AOL.com
Eli Lilly (LLY) Reports Positive Results for Omvoh in Phase 3 St - GuruFocus
Eli Lilly (LLY) Showcases Long-Term Efficacy of Omvoh for Crohn's Disease - GuruFocus
Crohn's patients stayed steroid-free 3 years on Eli Lilly's Omvoh - Stock Titan
CSL taps Lilly to de-risk IL-6 drug following dismal earnings - BioWorld MedTech
Eli Lilly and Company $LLY Shares Sold by Cumberland Partners Ltd - MarketBeat
L & S Advisors Inc Cuts Position in Eli Lilly and Company $LLY - MarketBeat
Synovus Financial Corp Reduces Stake in Eli Lilly and Company $LLY - MarketBeat
Cornerstone Advisors LLC Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Rznomics gets funding from Eli Lilly for researching hereditary hearing loss treatment - koreabiomed.com
FSU chemist earns Eli Lilly and Co. Grantee Award for contributions to biomedical, organic synthesis research | Newswise - Newswise
Eli Lilly Shares Face Mixed Sentiment Despite Clinical Advancements - AD HOC NEWS
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 YearsEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly and Company (NYSE:LLY) Shares Down 1.4%Here's What Happened - MarketBeat
A New GLP-1 Drug Being Developed May Come With a Surprising New Safety Concern - inc.com
Eli Lilly Shares Surge on Dual Clinical and Strategic Announcements - AD HOC NEWS
Jim Cramer Discusses Eli Lilly (LLY) & Weight Loss Drugs - Insider Monkey
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo - Benzinga
FSU chemist earns Eli Lilly and Co. Grantee Award for contributions to biomedical, organic synthesis research - Florida State University News
Eli Lilly Stock (LLY) in Focus as Zepbound Found to Help Treat Psoriasis - TipRanks
Daiwa Securities Group Forecasts Strong Price Appreciation for Eli Lilly and Company (NYSE:LLY) Stock - MarketBeat
Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns - Insider Monkey
First National Bank of Omaha Purchases Shares of 10,013 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by M&G PLC - MarketBeat
Eli Lilly (LLY) Clinical Trial Shows Improved Psoriasis Outcomes with Combination Therapy - GuruFocus
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study - CNBC
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? - Yahoo Finance
Lilly’s taltz and zepbound combination shows superior efficacy in psoriasis - Investing.com
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Psoriasis patients saw clearer skin and weight loss with dual Lilly drugs - Stock Titan
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider - GlobeNewswire Inc.
Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study - Fierce Biotech
CSL signs licensing deal with Eli Lilly for clazakizumab - WTVB
Eli Lilly (NASDAQ:LLY) Market Reaction Mirrors S&P 500 Futures Movement - Kalkine Media
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly
CSL signs licensing deal with Eli Lilly for clazakizumab By Reuters - Investing.com
CSL inks licensing deal with Eli Lilly, shares rise By Investing.com - Investing.com Canada
CSL inks licensing deal with Eli Lilly, shares rise - Investing.com
Eli Lilly Positions India as Pharma Export Hub, Boosting Logistics and Port Demand - Maritime Gateway
Eli Lilly (LLY) Secures License for Clazakizumab from CSL - GuruFocus
Eli Lilly Reports Phase 3 Win for Retevmo in Early Lung Cancer - GuruFocus
CSL signs licensing deal with Eli Lilly for clazakizumab to explore other potential treatments - Reuters
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Basketball legend Shaquille O’Neal named ambassador for Team USA Athlete Recovery Program in partnership with Eli Lilly - WTHR
Eli Lilly eyes India as global manufacturing hub amid rising drug demand - Business Standard
1 Reason I'd Buy Eli Lilly Stock and Never Sell - Yahoo Finance
Eli Lilly Stock (LLY) Rises on Plan to Invest $1 Billion in India - TipRanks
Eli Lilly stock price ticks up as India export-hub push and pipeline news grab attention - Bez Kabli
Eli Lilly’s Strategic Maneuvers in the Weight-Loss Drug Arena - AD HOC NEWS
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):